JW Pharmaceutical Corporation

A001060

KR7001060003

JW Pharmaceutical Corp is a Korea-based company engaged in the development and manufacture of pharmaceutical products. The Company mainly produces and sells drugs including supplying protein amino acids in blood, blood and fluid substitutes, hyperlipidemia agents, electrolyte additives, angina pectoris agents, rheumatoid arthritis drugs, perfusion fluid, prostatic hypertrophy drugs, hepatic coma drugs, and iron injections, among others. The Company also researches and develops anticancer drugs.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for JW Pharmaceutical Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29,600 KRW

Average target price

41,667 KRW

Spread / Average Target

+40.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JW PHARMACEUTICAL CORPORATION	-16.74%	50Cr
ELI LILLY AND COMPANY	+42.69%	75TCr
NOVO NORDISK A/S	+34.11%	61TCr
JOHNSON & JOHNSON	-6.87%	36TCr
MERCK & CO., INC.	+18.74%	33TCr
ABBVIE INC.	+6.76%	29TCr
ASTRAZENECA PLC	+18.08%	25TCr
ROCHE HOLDING AG	-3.44%	21TCr
NOVARTIS AG	+11.35%	21TCr
PFIZER, INC.	+2.64%	17TCr

Other Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 05/06/2024 am IST			5-day change	1st Jan Change
29,600 ^KRW	0.00%		+2.25%	-16.74%

27/05	Oncocross Expands Collaboration with JW Pharmaceutical on Developing Innovative New Drugs Using Ai in Anticancer and Regenerative Medicine	CI
14/05	JW Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Oncocross Expands Collaboration with JW Pharmaceutical on Developing Innovative New Drugs Using Ai in Anticancer and Regenerative Medicine	27/05	CI
JW Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	14/03	CI
CJ Logistics Secures Distribution Deal for JW Pharm's Intravenous Solutions	22/01	MT
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
South Korean Shares Touch Seven-Month Low on Concerns over US Fed Rate Hikes	20/23/20	MT
JW Pharmaceutical Faces Potential Fine of Nearly 30 Billion Won for Alleged Illegal Rebates	20/23/20	MT
JW Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
JW Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Celleron Therapeutics Ltd acquired Argonaut Therapeutics Limited from JW Pharmaceutical Corporation and Oxford Science Enterprises.	05/23/05	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
JW Pharmaceutical to Raise $3 Million via Share Sale	20/22/20	MT
JW Pharmaceutical Corporation announced that it expects to receive KRW 9.999993492 billion in funding	20/22/20	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
JW Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	21/22/21	CI
JW Pharmaceutical Corporation announced that it has received KRW 398.470716 million in funding	13/21/13	CI
JW Pharmaceutical Corporation announced that it expects to receive KRW 398.470716 million in funding	03/21/03	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/21/15	CI
JW Pharmaceutical Corporation(KOSE:A001060) dropped from KOSPI 200 Index	14/21/14	CI
JW Pharmaceutical Corporation announced that it has received KRW 300 million in funding	18/21/18	CI
Market Chatter: JW Pharmaceutical Gets German Health Body's Permit for Phase 2a Study of Oral Atopic Dermatitis Drug	21/21/21	MT
Market Chatter: South Korean Drugmakers Queue Up for Clearance of COVID-19 Treatments in January	04/21/04	MT
JW Pharmaceutical Corporation completed the acquisition of 50% stake in C&C Research Laboratories from Chugai Pharmaceutical Co., Ltd.	31/19/31	CI
JW Pharmaceutical Corporation agreed to acquire the remaining 50% stake in C&C Research Laboratories from Chugai Pharmaceutical Co., Ltd..	27/19/27	CI